Study Shows Drugs Have Comparable Residual Effects

MAY 01, 2006

The newer, short-acting, nonbenzodiazepine hypnotic drugs, such as zolpidem, have been touted because of their apparently reduced daytime residual effects, compared with other insomnia drugs. Finnish scientists determined zolpidem and the benzodiazepine sleep agent temazepam, however, to be equal in their next-day residual effects on certain psychomotor activities.

A double-blind, randomized, placebo-controlled study, published in Sleep Medicine (November 2003), compared the earlymorning driving ability of women who had taken zolpidem or temazepam at 2 AM. Five and a half hours after dosing, there were no significant differences in almost all measures of the patients' driving ability, when compared with placebo.

Interestingly, the patients who were administered zolpidem had more difficulty maintaining proper lane position, compared with the temazepam and placebo groups. The study also highlighted the varied patient susceptibility to the effects of the drugs—an important consideration when evaluating individual treatment options for insomnia.


Become a Respimat Top Performer 

Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc. 

Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today? 


Pharmacy Times Strategic Alliance

Pharmacist Education
Clinical features with downloadable PDFs

Next-Generation Pharmacist® Awards

3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference

Personalize the information you receive by selecting targeted content and special offers.